Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
2.870
-0.130 (-4.33%)
Mar 3, 2026, 4:00 PM EST - Market closed
Organogenesis Holdings Revenue
In the year 2025, Organogenesis Holdings had annual revenue of $564.17M with 17.04% growth. Organogenesis Holdings had revenue of $225.61M in the quarter ending December 31, 2025, with 78.13% growth.
Revenue (ttm)
$564.17M
Revenue Growth
+17.04%
P/S Ratio
0.65
Revenue / Employee
$660,619
Employees
854
Market Cap
369.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 564.17M | 82.13M | 17.04% |
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 742.90M |
| Ironwood Pharmaceuticals | 296.15M |
| Evolus | 285.82M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
| Lifecore Biomedical | 128.87M |
ORGO News
- 5 days ago - Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue - GlobeNewsWire
- 12 days ago - Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - Organogenesis Announces Initiation of Biologics License Application for ReNu® - GlobeNewsWire
- 2 months ago - Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain - GlobeNewsWire
- 2 months ago - Organogenesis: High-Tech Skin Substitute Company On Sale - Seeking Alpha
- 4 months ago - Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance - GlobeNewsWire